AIDS Alert Archives – November 1, 2008
November 1, 2008
View Archives Issues
-
Medicare Part D has big impact on HIV treatment interruptions
Some of the concerns and predictions HIV/AIDS advocates made two years ago about the impact of Medicare Part Dthe prescription drug benefiton HIV antiretroviral treatment appear to be coming true. -
Medicare Part D has many pitfalls for HIV/AIDS patients
As if HIV clinics and physicians didn't have enough government paperwork and bureaucracy to worry about, the nearly three-year-old Medicare Part D prescription drug coverage offers a labyrinth of obstacles, pitfalls, and other problems in keeping HIV patients adherent to their antiretroviral treatment (ART). -
Starpharma optimistic new microbicide will beat odds
Jackie Fairley, BVSc, BSc, MBA, chief executive officer of Starpharma of Victoria, Australia, recently fielded some questions from AIDS Alert about the company's investigational microbicide, VivaGel.® -
Research shows protective effect of male circumcision
Just-presented research at the XVII International AIDS Conference in Mexico City indicates that adult male circumcision continues to reduce the risk of acquiring HIV through heterosexual intercourse for at least 3.5 years. -
FDA Notifications
On Sept. 24, 2008, FDA approved a generic formulation of Didanosine (ddI) Delayed Release Capsules, 125 mg, 200 mg, 250 mg, and 400 mg, manufactured by Aurobindo Pharma Limited, Hyberdad, India. Didanosine is a Nucleoside Reverse Transcriptase Inhibitors (NRTI), which helps keep HIV, the virus that causes AIDS, from reproducing, and is intended to be used with other anti-retroviral agents for the treatment of HIV-1 infection. -
CDC underscores HIV threat to Latinos
HIV remains a significant threat to the health of Latino communities in the United States, the Centers for Disease Control and Prevention warns.